{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NO+Drug&page=2",
    "query": {
      "intervention": "NO Drug",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NO+Drug&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T12:50:52.340Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02559414",
      "title": "Antiplatelet Therapy in HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV",
        "Cardiovascular Diseases",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "21 Years to 80 Years"
      },
      "enrollment_count": 55,
      "start_date": "2015-02",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2018-10-15",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 2,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02559414"
    },
    {
      "nct_id": "NCT03936335",
      "title": "An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adverse Pregnancy Outcomes",
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "dupilumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 3930,
      "start_date": "2019-09-30",
      "completion_date": "2027-01-21",
      "has_results": false,
      "last_update_posted_date": "2025-08-03",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03936335"
    },
    {
      "nct_id": "NCT07423078",
      "title": "Window of Opportunity in Preserving Laryngeal Function Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)",
        "Locally Advanced Laryngeal Squamous Cell Carcinoma",
        "Hypopharyngeal Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Toripalimab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Matthew Spector",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2026-04-06",
      "completion_date": "2031-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07423078"
    },
    {
      "nct_id": "NCT01472536",
      "title": "A Study of Exclusion Criteria in a University Population",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Sequestration",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1400,
      "start_date": "2011-11",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2016-01-26",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01472536"
    },
    {
      "nct_id": "NCT00662571",
      "title": "Acamprosate: Genes Associated With Response",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alcoholism"
      ],
      "interventions": [
        {
          "name": "acamprosate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 485,
      "start_date": "2008-05",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-03-22",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662571"
    },
    {
      "nct_id": "NCT07321704",
      "title": "Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous Flap-Based Closure of Pilonidal Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pilonidal Disease"
      ],
      "interventions": [
        {
          "name": "Irrisept (0.05% chlorhexidine gluconate)",
          "type": "DEVICE"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Yosef Nasseri, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-02-17",
      "completion_date": "2027-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07321704"
    },
    {
      "nct_id": "NCT04659278",
      "title": "Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Drinking",
        "Alcohol Use, Unspecified",
        "Alcohol Abstinence",
        "Alcohol-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Endourage 1200 mg OMD ™ Oral Mucosal Drops",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Isolate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Peppermint Oil, masking flavor",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Endourage, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2025-09",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Novato, California",
      "locations": [
        {
          "city": "Novato",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04659278"
    },
    {
      "nct_id": "NCT02947750",
      "title": "Neurovascular Transduction During Exercise in Chronic Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Insufficiency, Chronic"
      ],
      "interventions": [
        {
          "name": "6R-BH4",
          "type": "DRUG"
        },
        {
          "name": "6R-BH4 placebo",
          "type": "OTHER"
        },
        {
          "name": "Folic acid",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise training",
          "type": "OTHER"
        },
        {
          "name": "Stretching",
          "type": "OTHER"
        },
        {
          "name": "Histidine and beta-alanine supplementation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Histidine and beta-alanine placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 150,
      "start_date": "2016-10",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Decatur, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02947750"
    },
    {
      "nct_id": "NCT04724018",
      "title": "Sacituzumab Govitecan Plus EV in Metastatic UC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Cancer",
        "Metastatic Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan (SG)",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab vedotin-ejfv (EV)",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2021-05-20",
      "completion_date": "2028-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04724018"
    },
    {
      "nct_id": "NCT01354210",
      "title": "Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patient Adherence",
        "HIV"
      ],
      "interventions": [
        {
          "name": "SMS Text Message Reminder",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Ann & Robert H Lurie Children's Hospital of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "16 Years to 29 Years"
      },
      "enrollment_count": 110,
      "start_date": "2010-10",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-09-27T12:50:52.340Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01354210"
    }
  ]
}